Background/Aims The role of reactivation of human cytomegalovirus (HCMV) in determining outcomes of cirrhotic patients with acute decompensation (AD) is unknown. We aimed to investigate HCMV incidence and potential correlation with hepatic outcomes in AD patients.
Methods Two prospective multicentre cohorts with AD patients were investigated. Patients in cohort 1 were recruited from 4 centres, while patients in cohort 2 were randomly selected from a second multicentre cohort. HCMV reactivation was established with quantitative real-time polymerase chain reaction assay in seropositive patients.
Results HCMV reactivation was found in 35 patients from cohort 1 (n=722) and 14 from cohort 2 (n=291), with an incidence of 4.8% in both cohorts. Bacterial infection and liver failure were independently correlated with HCMV reactivation. HCMV reactivation was an independent predictor of 90-day mortality. Among bacterial infection populations in these two cohorts, patients with HCMV reactivation had worse prognosis compared to those without. Incidence of acute-on-chronic liver failure (ACLF) was higher in patients with HCMV reactivation compared to those without and was also independently correlated with development of ACLF. In a total of 49 HCMV reactivation cases, 8 patients were treated with ganciclovir, in whom a significantly lower 90-day mortality compared with those not treated was observed. All 3 patients who underwent liver transplantation with reactivation of HCMV died.
Conclusions In AD patients, HCMV reactivation was common, especially in those with bacterial infection or liver failure, and they were more prone to having ACLF and 90‑day mortality. The data propose the need for active surveillance for HCMV infection in AD patients.
Citations
Citations to this article as recorded by
Human cytomegalovirus reactivation in decompensated cirrhosis: marker of immunosuppression or contributor to severity?: Editorial on “Human cytomegalovirus reactivation in cirrhosis patients with acute decompensation” Zhujun Cao, Richard Moreau Clinical and Molecular Hepatology.2026; 32(2): 953. CrossRef
Correspondence to editorial on “Human cytomegalovirus reactivation in cirrhosis patients with acute decompensation” Changze Hong, Jinjun Chen Clinical and Molecular Hepatology.2026; 32(2): e227. CrossRef
Call for preemptive treatment of cytomegalovirus in patients with cirrhosis and acute decompensation: Editorial on “Human cytomegalovirus reactivation in cirrhosis patients with acute decompensation” Norihiro Imai Clinical and Molecular Hepatology.2026; 32(2): 949. CrossRef
Gestational and Congenital Toxoplasmosis: An Updated Review with Emphasis on High-Prevalence Countries Alan Roberto Hatanaka, Antonio Braga, Evelyn Traina, Larissa Keren de Azevedo Teixeira, Carolina Longo, Pedro Teixeira Castro, Heron Werner, Gustavo Yano Callado, Edward Araujo Júnior Women.2026; 6(3): 43. CrossRef
Backgrounds/Aims Sarcomatoid hepatocellular carcinoma (HCC) is a rare histological subtype of HCC characterized by extremely poor prognosis; however, its molecular characterization has not been elucidated.
Methods In this study, we conducted an integrated multiomics study of whole-exome sequencing, RNA-seq, spatial transcriptome, and immunohistochemical analyses of 28 paired sarcomatoid tumor components and conventional HCC components from 10 patients with sarcomatoid HCC, in order to identify frequently altered genes, infer the tumor subclonal architectures, track the genomic evolution, and delineate the transcriptional characteristics of sarcomatoid HCCs.
Results Our results showed that the sarcomatoid HCCs had poor prognosis. The sarcomatoid tumor components and the conventional HCC components were derived from common ancestors, mostly accessing similar mutational processes. Clonal phylogenies demonstrated branched tumor evolution during sarcomatoid HCC development and progression. TP53 mutation commonly occurred at tumor initiation, whereas ARID2 mutation often occurred later. Transcriptome analyses revealed the epithelial–mesenchymal transition (EMT) and hypoxic phenotype in sarcomatoid tumor components, which were confirmed by immunohistochemical staining. Moreover, we identified ARID2 mutations in 70% (7/10) of patients with sarcomatoid HCC but only 1–5% of patients with non-sarcomatoid HCC. Biofunctional investigations revealed that inactivating mutation of ARID2 contributes to HCC growth and metastasis and induces EMT in a hypoxic microenvironment.
Conclusions We offer a comprehensive description of the molecular basis for sarcomatoid HCC, and identify genomic alteration (ARID2 mutation) together with the tumor microenvironment (hypoxic microenvironment), that may contribute to the formation of the sarcomatoid tumor component through EMT, leading to sarcomatoid HCC development and progression.
Citations
Citations to this article as recorded by
Sequential anlotinib and camrelizumab combination therapy achieves exceptional survival in multi-driver mutated, TMB-low/PD-L1-low/MSS pulmonary sarcomatoid carcinoma: case report and literature review Jun Zhu, Ai Zhu, Gang Li, Lidong Liu, Ziran Gao, Jiayun Liu, Yunfei Ye, Xunzhi Zhu, Yi Li, Hong Chen, Meijin Huang Frontiers in Immunology.2026;[Epub] CrossRef
Emerging trends and converging evidence in tumor evolution: A comprehensive review Chenqi Jin, Weiqi Li, Boqiang Liu, Lu-Qi Cao, Sven Marcel Stefan, Luoxi Yuan, Xin Yu, Liang Shi, Hong Yu Drug Resistance Updates.2026; 86: 101380. CrossRef
Hepatic carcinosarcoma with predominant sarcomatous component mimicking intrahepatic cholangiocarcinoma: a case report and literature review Xuda Ji, Meijia Fu, Fangfeng Liu Frontiers in Medicine.2026;[Epub] CrossRef
Establishment and characterization of a novel HBV-integrated hepatic sarcomatoid carcinoma cell line Jiayin Dai, Fang Cao, Zhenli Yang, Kun Dong, Xiaozheng Huang, Xiaocui Bian, Yuqin Liu Human Cell.2026;[Epub] CrossRef
Pathogenetic features of sarcomatoid carcinoma G. G. Freynd, I. S. Chub Perm Medical Journal.2026; 43(2): 5. CrossRef
Integration of histopathology and molecular features for the classification of benign and malignant hepatocellular neoplasms Christine Sempoux, Young Nyun Park Virchows Archiv.2026;[Epub] CrossRef
Curative response to combined targeted-immunotherapy for post-hepatectomy lymph node metastasis in sarcomatoid hepatocellular carcinoma: case report and literature review Pan Liu, Song Zhang, Xiao-Ming Xin, Min Jing, Lie-Dong Wen, Xin Xiang, Shun-Hai Liu Frontiers in Oncology.2025;[Epub] CrossRef
Comparison of stereotactic body radiotherapy following transcatheter arterial chemoembolization vs transcatheter arterial chemoembolization alone in hepatocellular carcinoma Lin Chen, Liang Wang, Hui Wang World Journal of Gastrointestinal Surgery.2025;[Epub] CrossRef
First
Prev
